IFNA17 and chronic myelogenous leukemia, BCR-ABL1 positive: A substantial number of patients entering vaccine trials (42 patients, 38.5%) were treated with IFN-α before starting imatinib; however, according to the inclusion criteria, they still showed measurable CML before starting vaccination.